<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018313</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P39 1.1</org_study_id>
    <nct_id>NCT04018313</nct_id>
  </id_info>
  <brief_title>To Compare the PK and Safety of Omalizumab(CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of Three Formulations of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare
      the Pharmacokinetics and Safety of Three Formulations of Omalizumab (CT-P39, EU-approved
      Xolair, and US-licensed Xolair) in Healthy Subjects
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety]</measure>
    <time_frame>up to day 127</time_frame>
    <description>Treatment-Emergent Adverse Events (TEAEs) of CT-P39, compared to that of EU-approved Xolair in healthy subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Outcome Measures [AUC0-inf]</measure>
    <time_frame>up to day 127</time_frame>
    <description>Area Under the concentration-time Curve from time zero to infinity (AUC0-inf) of CT-P39, EU approved Xolair, and US-licensed Xolair in healthy subjects (CT-P39 to EU approved Xolair, CT-P39 to US licensed Xolair, and EU-approved Xolair to US licensed Xolair)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Outcome Measures [AUC0-last]</measure>
    <time_frame>up to day 127</time_frame>
    <description>Area Under the concentration-time Curve from time zero to the last quantifiable concentration (AUC0-last) of CT-P39, EU approved Xolair, and US-licensed Xolair in healthy subjects (CT-P39 to EU approved Xolair, CT-P39 to US licensed Xolair, and EU-approved Xolair to US licensed Xolair)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Outcome Measures [Cmax]</measure>
    <time_frame>up to day 127</time_frame>
    <description>Maximum serum concentration (Cmax) of CT-P39, EU approved Xolair, and US-licensed Xolair in healthy subjects (CT-P39 to EU approved Xolair, CT-P39 to US licensed Xolair, and EU-approved Xolair to US licensed Xolair)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Outcome Measures [Tmax]</measure>
    <time_frame>up to day 127</time_frame>
    <description>To assess Time to Cmax (Tmax) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Outcome Measures [t1/2]</measure>
    <time_frame>up to day 127</time_frame>
    <description>To assess Terminal half-life (t1/2) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Outcome Measures [%AUCext]</measure>
    <time_frame>up to day 127</time_frame>
    <description>To assess Percentage of AUC0-inf obtained by extrapolation (%AUCext) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Outcome Measures [λz]</measure>
    <time_frame>up to day 127</time_frame>
    <description>To assess Terminal elimination rate constant (λz) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Outcome Measures [Apparent total body clearance (CL/F)]</measure>
    <time_frame>up to day 127</time_frame>
    <description>To assess Apparent total body clearance (CL/F) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Outcome Measures [Mean residence time (MRT)]</measure>
    <time_frame>up to day 127</time_frame>
    <description>To assess Mean residence time (MRT) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics [IgE level]</measure>
    <time_frame>up to day 127</time_frame>
    <description>Free IgE and total IgE levels (the sum of free and omalizumab-bound IgE) in the serum samples from subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse events of Special Interest [Safety]</measure>
    <time_frame>up to day 127</time_frame>
    <description>Adverse events of Special Interest (AESI) of CT-P39, EU approved Xolair, and US-licensed Xolair in healthy subjects (e.g., Allergic reactions type 1/anaphylaxis, injection site reactions, serum sickness/serum sickness-like reactions, and parasitic infections)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">177</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CT-P39 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg/mL, Solution for injection in PFS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU-approved Xolair (Part 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg/mL, Solution for injection in PFS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT-P39 (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg/mL, Solution for injection in PFS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU-approved Xolair (Part 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg/mL, Solution for injection in PFS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US-licensed Xolair (Part 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg/mL, Solution for injection in PFS</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P39</intervention_name>
    <description>150 mg/mL, Solution for injection in PFS</description>
    <arm_group_label>CT-P39 (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EU-approved Xolair</intervention_name>
    <description>150 mg/mL, Solution for injection in PFS</description>
    <arm_group_label>EU-approved Xolair (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P39</intervention_name>
    <description>150 mg/mL, Solution for injection in PFS</description>
    <arm_group_label>CT-P39 (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EU-approved Xolair</intervention_name>
    <description>150 mg/mL, Solution for injection in PFS</description>
    <arm_group_label>EU-approved Xolair (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>US-licensed Xolair</intervention_name>
    <description>150 mg/mL, Solution for injection in PFS</description>
    <arm_group_label>US-licensed Xolair (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subject (male or female) between the ages of 18 and 55 years.

          -  Subject with a body weight of &gt; 40 kg and ≤ 90 kg and a BMI between 18.0 kg/m2 and
             29.9 kg/m2(both inclusive).

          -  Subject with an IgE level of ≤ 100 IU/mL.

        Exclusion Criteria:

          -  Subject has a medical history and/or current presence of disease including one or more
             of the allergic reaction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>MinJi Ma</last_name>
    <phone>+82328505720</phone>
    <email>minji.ma@celltrion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phase 1 unit</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Phase 1 unit</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

